| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/30/2003 | WO2003008444A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008443A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008376A2 Adhesive dopa-containing polymers and related methods of use |
| 01/30/2003 | WO2003008186A1 Insulating and functionalizing fine metal-containing particles with comformal ultra-thin films |
| 01/30/2003 | WO2003007996A1 Drug delivery systems and treatments using them |
| 01/30/2003 | WO2003007995A2 Pharmaceutical preparations containing ion exchange resins charged with fluoroquinolone |
| 01/30/2003 | WO2003007989A1 Anti-microbial targeting chimeric pharmaceutical |
| 01/30/2003 | WO2003007988A1 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
| 01/30/2003 | WO2003007982A1 Sustained release hgf hydrogel preparations |
| 01/30/2003 | WO2003007978A1 Alpha-fetoprotein peptides and uses thereof |
| 01/30/2003 | WO2003007971A1 Improved heteropolymer complexes and methods for their use |
| 01/30/2003 | WO2003007967A1 Medical preparation for parenteral injection |
| 01/30/2003 | WO2003007957A1 Method and composition for treatment of cancer |
| 01/30/2003 | WO2003007928A1 Ascites preventives for poultry |
| 01/30/2003 | WO2003007922A2 Pharmaceutical formulation containing an ltb4 antagonist |
| 01/30/2003 | WO2003007920A1 Antihistamine formulations for soft capsule dosage forms |
| 01/30/2003 | WO2003007919A1 Controlled drug delivery systems providing variable release rates |
| 01/30/2003 | WO2003007918A1 Zero order controlled drug delivery system |
| 01/30/2003 | WO2003007917A1 Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| 01/30/2003 | WO2003007912A2 Lyophilized formulation comprising olanzapine |
| 01/30/2003 | WO2003007907A1 Water-free ubichinon concentrate |
| 01/30/2003 | WO2003007889A2 Therapeutic agents comprising pro-apoptotic proteins |
| 01/30/2003 | WO2003007881A2 Antibodies specific for nanotubes and related methods and compositions |
| 01/30/2003 | WO2003007874A2 Anti-tumor activity from reptile serum |
| 01/30/2003 | WO2003007867A2 A salt/ion pair medicinal aerosol formulation |
| 01/30/2003 | WO2003007782A2 Biodegradable injectable implants and related methods of manufacture and use |
| 01/30/2003 | WO2003007733A1 Protein-containing foodstuff comprising a cross-linking enzyme and a hydrocolloid |
| 01/30/2003 | WO2003007686A2 Use of copper chelators to inhibit the inactivation of protein c |
| 01/30/2003 | WO2002089817A3 Anti-virus agent |
| 01/30/2003 | WO2002069945A3 Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors |
| 01/30/2003 | WO2002066002A3 Pharmaceutical formulation |
| 01/30/2003 | WO2002064116A3 Thermolabile liposome with controlled release temperature |
| 01/30/2003 | WO2002056825A3 Composition and method to increase calcium levels in animals |
| 01/30/2003 | WO2002055101A3 Storage stable powder compositions of interleukin-4 receptor |
| 01/30/2003 | WO2002053097A3 Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| 01/30/2003 | WO2002049573A3 Novel in-situ forming controlled release microcarrier delivery system |
| 01/30/2003 | WO2002034879A3 Method for introducing antisense oligonucleotides into eucaryotic cells |
| 01/30/2003 | WO2002034200A3 Transdermal therapeutic systems comprising photosensitive active substances |
| 01/30/2003 | WO2002030394A3 Medicinal aerosol formulations |
| 01/30/2003 | WO2002026215A3 Thermogelling biodegradable aqueous polymer solution |
| 01/30/2003 | WO2002024232A3 Pei: dna vector formulations for in vitro and in vivo gene delivery |
| 01/30/2003 | WO2002013873A9 P97-active agent conjugates and their methods of use |
| 01/30/2003 | WO2002007773A3 Multi-component biological transport systems |
| 01/30/2003 | US20030023104 For prolonging or altering the activity of a compound which is a member of the chlorambucil family |
| 01/30/2003 | US20030023091 For therapy and prophylaxis of peptic ulcers, gastro intestinal inflammatory diseases like duodenal/ gastric ulcer or gastritis or other gastro intestinal disorders |
| 01/30/2003 | US20030023084 For use in the oral hygiene |
| 01/30/2003 | US20030023049 Site specific protein modification |
| 01/30/2003 | US20030023048 Chemical modification of proteins to improve biocompatibility and bioactivity |
| 01/30/2003 | US20030022944 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/30/2003 | US20030022940 Novel pharmaceutical formulations of modafinil |
| 01/30/2003 | US20030022921 Stable pharmaceutical formulation comprising torsemide modification II |
| 01/30/2003 | US20030022880 Soluble forms of amoxicillin and treatment of animals |
| 01/30/2003 | US20030022877 Method of increasing testosterone and related steroid concentrations in women |
| 01/30/2003 | US20030022876 Sustained-release analgesic compounds |
| 01/30/2003 | US20030022861 Delivery of genetic material via solution of dextrin derivatives; gene therapy; immunotherapy |
| 01/30/2003 | US20030022852 Biodegradable immunomodulatory formulations and methods for use thereof |
| 01/30/2003 | US20030022843 Toluene sulfonamide - containing anti- tumor composition and method of use thereof |
| 01/30/2003 | US20030022831 Compositions employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of compound conjugated to reagent across one or more layers of tissue, compared to non-conjugated compound |
| 01/30/2003 | US20030022828 A growth factor formulation comprising: a polypeptide of the TGF- beta (tranformation growth factor) superfamily, N-vinyl-2-pyrrolidone polymer carrier and a solvent selected from water and aqueous buffer solutions |
| 01/30/2003 | US20030022308 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
| 01/30/2003 | US20030022149 Enhanced production of safe plasma preparations |
| 01/30/2003 | US20030021854 Nanocrystal microbiocide metal |
| 01/30/2003 | US20030021848 Supplying to arteries at time of angioplasty |
| 01/30/2003 | US20030021846 Sustained release; wet granulation, compaction |
| 01/30/2003 | US20030021845 Gastroretentive controlled release pharmaceutical dosage forms |
| 01/30/2003 | US20030021843 Antidiabetic preparation for oral administration |
| 01/30/2003 | US20030021842 Means for creating a mass having structural integrity |
| 01/30/2003 | US20030021840 High dose solid unit oral pharmaceutical dosage form of amorphous nelfinavir mesylate and process for making same |
| 01/30/2003 | US20030021829 Removal eye dryness; adsorption polyvinylpyrrolidone |
| 01/30/2003 | US20030021820 Dissolvable oxides for biological applications |
| 01/30/2003 | US20030021794 Heat shock protein-based vaccines and immunotherapies |
| 01/30/2003 | US20030021793 Polyanionic polymers as adjuvants for mucosal immunization |
| 01/30/2003 | US20030021792 Quantitative analysis; immunosuppressants, anticoagulants |
| 01/30/2003 | US20030021791 Complexing enzyme with antibody; trapping within tumor |
| 01/30/2003 | US20030021790 Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
| 01/30/2003 | US20030021781 Administering antibodies |
| 01/30/2003 | US20030021779 Immunology response; monoclonal antibodies |
| 01/30/2003 | US20030021765 Polymer conjugates of interferon beta-1a and uses |
| 01/30/2003 | US20030021759 Cosmetic formulations of quaternary ammonium compounds incorporating polyhydric alcohols |
| 01/30/2003 | US20030021755 Headache therapy |
| 01/30/2003 | US20030021754 Aerosols; vaporization, cooling |
| 01/30/2003 | US20030021753 Delivery of antiemetics through an inhalation route |
| 01/30/2003 | CA2457308A1 Controlled drug delivery systems providing variable release rates |
| 01/30/2003 | CA2457304A1 Zero order controlled drug delivery system |
| 01/30/2003 | CA2454345A1 Anti-tumor activity from reptile serum |
| 01/30/2003 | CA2454226A1 Improved heteropolymer complexes and methods for their use |
| 01/30/2003 | CA2453993A1 Method and composition for treatment of cancer |
| 01/30/2003 | CA2453986A1 Glycoprotein vi fusion proteins |
| 01/30/2003 | CA2453967A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453965A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453765A1 Polysaccharidic esters of retinoic acid |
| 01/30/2003 | CA2453720A1 A salt/ion pair medicinal aerosol formulation |
| 01/30/2003 | CA2453616A1 Pharmaceutical preparations containing ion exchange resins charged with active ingredients |
| 01/30/2003 | CA2453473A1 Water-free ubichinon concentrate |
| 01/30/2003 | CA2453342A1 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
| 01/30/2003 | CA2453290A1 Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| 01/30/2003 | CA2452556A1 Protein-containing foodstuff comprising a coss-linking enzyme and a hydrocolloid |
| 01/30/2003 | CA2452421A1 Anti-microbial targeting chimeric pharmaceutical |
| 01/30/2003 | CA2452357A1 Pharmaceutical formulation containing an ltb4 antagonist |
| 01/30/2003 | CA2448724A1 2-methyl-thieno-benzodiazepine lyophilized formulation |